

**CORRIGENDA****miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma**

X Zhou, CZ Zhang, S-X Lu, GG Chen, L-Z Li, L-L Liu, C Yi, J Fu, W Hu, J-M Wen and J-P Yun

*Oncogene* (2016) 35, 5078; doi:10.1038/onc.2016.61; published online 8 August 2016**Correction to:** *Oncogene* (2015) 34, 965–977; doi:10.1038/onc.2014.35; published online 17 March 2014

Since the online publication of this article the authors realised that one of the serial numbers for the grants from the National Natural Science Foundation of China was quoted incorrectly in the Acknowledgements. The correct serial numbers are No. 81172345, 81201717. The Acknowledgements should therefore read as follows:

**ACKNOWLEDGEMENTS**

This study was supported by grants from the National Natural Science Foundation of China (No. 81172345, 81201717), and the Project of State Key Laboratory of Oncology in South China.

The authors apologise for any inconvenience caused by this error.

**Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing**

K-T Lin, Y-J Shann, G-Y Chau, C-N Hsu and C-YF Huang

*Oncogene* (2016) 35, 5078; doi:10.1038/onc.2016.62; published online 1 August 2016**Correction to:** *Oncogene* (2014) 33, 4786–4794; doi:10.1038/onc.2013.424; published online 21 October 2013

Following the publication of this article the authors noticed an error in the equation of FGFR2-IIIc inclusion ratio in the Materials

and methods section. The correct equation is shown below:

$$FGFR2-IIIc \text{ inclusion ratio} = 2^{-(IIIc^{\Delta Ct} - IIIb^{\Delta Ct})} / (2^{-(IIIc^{\Delta Ct} - IIIb^{\Delta Ct})} + 1)$$

The authors apologise for any inconvenience caused by this error.